Table 1.

clinical studies data on the treatment of HNC with interventional nanotheranostics.

Study Ids	Status	Phase	Study Start	Study Completion	Remark	NCT Number
08-084	Completed	Phase 1	August 2008	August 2016	Nab-paclitaxel + cetuximab + intensity-modulated radiation therapy (IMRT) used 25 patients were involved Common AE observed was lymphopenia Efficacy for 2-year overall survival was found 91%	NCT00736619
STU 072010-046	Completed	Phase 1 Phase 2	March 1, 2009	August 3, 2015	Nab-paclitaxel, cisplatin, and cetuximab are used 34 patients were involved	NCT00851877
BIND-014-001	Completed	Phase 1	January 2011	February 2016	Docetaxel is used as a drug moiety 52 patients were involved Recommended dose was 60 mg/m2	NCT01300533
201202113	Completed	Phase 2	August 9, 2012	October 31, 2019	Induction chemotherapy +cisplatin+ radiation therapy 30 patients were enrolled Swallowing, oral pain and voice quality were improved along with the therapeutic upliftment	NCT01566435
NCI-2012-02179	Active, not recruiting	Phase 1	March 26, 2013	December 2022	Nav-paclitaxel-based induction + nab-paclitaxel-based concurrent chemotherapy + re-irradiation 48 patients were involved Recommended dose was 100 mg/m2	NCT01847326
IRB17-0104	Active, not recruiting	Phase 2	June 27, 2017	July 2023	39 patients were enrolled Radiography+ systemic therapy	NCT03107182
NCI-2021-00122	Recruiting	Phase 2	April 7, 2021	September 30, 2026	NBTXR3, Radiation Therapy, and Pembrolizumab Administered in intertumoral/intranodal 60 participants involved	NCT04862455
SNB101P01	Unknown	Phase 1	October 21, 2020	March 31, 2022	36 participants enrolled Drug: SNB-101	NCT04640480